Dosing Begins in Phase 1 Trial of CERC-007

Dosing Begins in Phase 1 Trial of CERC-007

284658

Dosing Begins in Phase 1 Trial of CERC-007

Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll up to 30 adult patients who received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and a CD38 inhibitor. Recruitment is ongoing at four U.S. sites. Initial data is expected in the next couple of months, the company announced. “We are very excited to…

You must be logged in to read/download the full post.